Laser-guided Treatment Better in Long Term than Monitoring for Low-risk Prostate Cancer, New Phase 3 Data Show

Laser-guided Treatment Better in Long Term than Monitoring for Low-risk Prostate Cancer, New Phase 3 Data Show
Prostate cancer patients who undergo a nonsurgical procedure to remove part of their prostate gland — using a kind of photodynamic therapy targeting the blood vessels — fare better in the long term than those under active surveillance, according to updated Phase 3 data. The approach, called vascular-targeted photodynamic therapy, or VTP, uses a light-sensitive drug called WST11 that releases toxic, free radicals when activated. The drug is injected into the bloodstream and activated with a laser — coming from optical fibers inserted directly into the prostate — killing the surrounding cancer cells. Trial results after four years of follow-up show that low-risk prostate cancer patients who receive this treatment are significantly less likely to require more aggressive treatments like surgery or radiation therapy. However, the rate of patients developing metastasis over the four years and the rate of patients who died from overall causes or from prostate cancer were similar among the two treatment approaches. These results were recently shared in a presentation titled, “Four-year follow-up of a phase-3 prospective randomized trial of vascular-targeted phototherapy versus active surveillance for low-risk prostate cancer,” at the American Urologic Association Meeting in San Francisco. In many cases of low-risk prostate cancer, active surveillance is an appropriate treatment option that reduces the consequences of o
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *